The Rise and Fall of Vaxzevria

From lifesaver to legal headache, explore how AstraZeneca's COVID-19 vaccine went from global hero to zero amidst controversial side effects and shifting scientific standards.

AstraZeneca has finally caved, pulling its COVID-19 vaccine, Vaxzevria, off the global market. 

The official reason? 

A surplus of newer, supposedly more effective vaccines tailored to emerging COVID-19 variants has made Vaxzevria obsolete. 

But let’s cut through the corporate speak: this withdrawal follows hot on the heels of AstraZeneca's own admission that Vaxzevria is linked to rare but deadly side effects like Thrombosis with Thrombocytopenia Syndrome (TTS), involving severe blood clots and low blood platelet counts.

These serious risks came to light following a slew of lawsuits claiming the vaccine caused deaths and grievous injuries. 

Despite these grave concerns, AstraZeneca has the gall to boast about Vaxzevria’s role in mitigating the pandemic, asserting it saved millions of lives. 

Meanwhile, the Serum Institute of India, which produced the vaccine under the brand Covishield, stopped production back in December 2021 due to falling demand.

In a move that reeks of damage control, AstraZeneca and the Serum Institute have stressed their commitment to transparency, claiming they've been upfront about the vaccine's potential dangers from the beginning. 

However, the timing of these withdrawals and the backdrop of legal challenges paints a different picture… one where public safety seems to have taken a backseat to corporate interests until the pressure became too great to ignore.

In classic corporate fashion, AstraZeneca insists the decision to withdraw Vaxzevria is purely coincidental and unrelated to the lawsuits or the vaccine’s harmful side effects. 

But for those of us skeptical of big pharma’s motives, this move raises serious questions about the prioritisation of public health over profit margins.

In more positive news, let's give a nod to the German Cancer Research Center for some actual scientific progress with their latest study on intermittent fasting. 

This isn't just about shedding a few pounds, it's about saving livers and lives. 

They've shown in mice that sticking to a 5:2 fasting schedule can slam the brakes on fatty liver disease and dramatically cut down on the risk of liver inflammation and cancer.

These implications are huge and could revolutionise how we prevent and treat serious liver diseases.

It’s no secret that our diets can be our greatest medicine and our most potent poison.

If you’re confused about which diet/plan is best for you and your health, book a complimentary 30-minute appointment with me and I’ll do my best to help.

Book right here:

Chat soon!
Marko

Reply

or to participate.